Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1692443

registered interest
date	28/02/2024
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Probate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what the average time taken is from submission of application to granting of probate in the last 12 months.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	16212
answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>HMCTS is focused on increasing outputs to reduce overall timeliness on all types of applications, and the average mean length of time taken for a grant of probate, from submission, is 12.6 weeks in the last 12 months (October 2022 to September 2023) and following receipt of the documents required, is 10.8 weeks. The probate service received record levels of applications during 2022 and this has continued to grow, with higher levels of receipts during January to September 2023 compared to the same period in 2022.</p><p> </p><p>HMCTS has increased staffing levels, streamlined internal processes and continued to invest in further improving the digital service.</p><p> </p><p>As a result, the number of grants issued for recent months has been at record levels, with around 16,000 more grants issued than applications received during the last four months (September to December 2023), using more recent management information published by HMCTS (which does not go through the same level of quality assurance and analysis as the Family Court Statistics Quarterly).</p><p>Average waiting times for probate grants are routinely published on GOV.UK via Family Court Statistics Quarterly, and currently cover the period up to September 2023: <a href="https://www.gov.uk/government/collections/family-court-statistics-quarterly" target="_blank">https://www.gov.uk/government/collections/family-court-statistics-quarterly</a>.</p> answering member constituency Finchley and Golders Green answering member printed Mike Freer grouped question UIN 16213 question first answered 07/03/2024 14:20:58 answering member 4004 label Biography information for Mike Freer
tabling member	4623 label Biography information for Tonia Antoniazzi

1692444

registered interest
date	28/02/2024
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Probate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what steps his Department is taking to reduce waiting times for the granting of probate.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	16213
answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>HMCTS is focused on increasing outputs to reduce overall timeliness on all types of applications, and the average mean length of time taken for a grant of probate, from submission, is 12.6 weeks in the last 12 months (October 2022 to September 2023) and following receipt of the documents required, is 10.8 weeks. The probate service received record levels of applications during 2022 and this has continued to grow, with higher levels of receipts during January to September 2023 compared to the same period in 2022.</p><p> </p><p>HMCTS has increased staffing levels, streamlined internal processes and continued to invest in further improving the digital service.</p><p> </p><p>As a result, the number of grants issued for recent months has been at record levels, with around 16,000 more grants issued than applications received during the last four months (September to December 2023), using more recent management information published by HMCTS (which does not go through the same level of quality assurance and analysis as the Family Court Statistics Quarterly).</p><p>Average waiting times for probate grants are routinely published on GOV.UK via Family Court Statistics Quarterly, and currently cover the period up to September 2023: <a href="https://www.gov.uk/government/collections/family-court-statistics-quarterly" target="_blank">https://www.gov.uk/government/collections/family-court-statistics-quarterly</a>.</p> answering member constituency Finchley and Golders Green answering member printed Mike Freer grouped question UIN 16212 question first answered 07/03/2024 14:20:58 answering member 4004 label Biography information for Mike Freer
tabling member	4623 label Biography information for Tonia Antoniazzi

1689181

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	14114
answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14115 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4623 label Biography information for Tonia Antoniazzi

1689182

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	14115
answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14114 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4623 label Biography information for Tonia Antoniazzi